Company profile for Shenzhen Chipscreen Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

CHIPSCREEN BIOSCIENCES was established in March 2001, and is currently a leading enterprise of small molecule innovative medicines in China. CHIPSCREEN BIOSCIENCES puts as the first priority to meet unmet clinical needs. It insists on an “original, safe, excellent and effective China,” and is dedicated in providing patients with affordable innovative mechanisms of therapeutic drugs”. CHIPSCREEN BIOSCIENCES owns headquart...
CHIPSCREEN BIOSCIENCES was established in March 2001, and is currently a leading enterprise of small molecule innovative medicines in China. CHIPSCREEN BIOSCIENCES puts as the first priority to meet unmet clinical needs. It insists on an “original, safe, excellent and effective China,” and is dedicated in providing patients with affordable innovative mechanisms of therapeutic drugs”. CHIPSCREEN BIOSCIENCES owns headquarters, research and development centers, GMP production bases in Shenzhen and Chengdu, and the Beijing clinical research center and Shanghai commercial center, which is a four-in-one modern biomedicine group company.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
Rooms 601-606, Building 2, Hi-tech Incubator Building, High-tech No. 1 Road, N...
Telephone
Telephone
+86-0755-26957330
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/chipscreen-biosciences-brain-penetrant-aurora-b-selective-inhibitor-cs231295-tablet-receives-fda-ind-approval-advancing-global-clinical-development-302518530.html

PR NEWSWIRE
31 Jul 2025

https://www.prnewswire.com/news-releases/the-phase-iii-clinical-trial-application-for-first-line-treatment-of-extensive-disease-small-cell-lung-cancer-with-chiauranib-has-been-approved-302294039.html

PR NEWSWIRE
01 Nov 2024

https://www.prnewswire.com/news-releases/chipscreen-biosciences-innovative-anti-tumor-drug-cs231295-tablets-investigational-new-drug-ind-application-accepted-302279370.html

PR NEWSWIRE
17 Oct 2024

https://www.prnewswire.com/news-releases/chiglitazar-for-the-treatment-of-mash-phase-ii-clinical-study-selected-for-oral-presentation-at-the-2024-american-liver-disease-annual-meeting-302276529.html

PR NEWSWIRE
15 Oct 2024

https://www.prnewswire.com/news-releases/national-medical-products-administration-nmpa-approves-chipscreen-biosciences-chidamide-epidaza-combined-with-r-chop-for-the-treatment-of-diffuse-large-b-cell-lymphoma-302131654.html

PR NEWSWIRE
30 Apr 2024

https://www.prnewswire.com/news-releases/positive-results-from-phase-ii-clinical-trial-cgz203-study-of-chiglitazar-monotherapy-for-non-alcoholic-steatohepatitis-302091430.html

PR NEWSWIRE
18 Mar 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty